(NASDAQ: ETNB) 89bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.75%.
89bio's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast ETNB's revenue for 2027 to be $9,561,234,000, with the lowest ETNB revenue forecast at $8,655,402,151, and the highest ETNB revenue forecast at $10,467,065,849. On average, 3 Wall Street analysts forecast ETNB's revenue for 2028 to be $40,513,530,189, with the lowest ETNB revenue forecast at $11,583,844,842, and the highest ETNB revenue forecast at $74,656,310,675.
In 2029, ETNB is forecast to generate $116,975,081,258 in revenue, with the lowest revenue forecast at $47,938,285,685 and the highest revenue forecast at $212,552,968,992.